Recently, multinational pharmaceutical giant Novartis announced an agreement to acquire Sinovac Pharmaceuticals, strengthening its presence in the field of kidney disease.
Xinruinuo Pharmaceuticals is a clinical stage Chinese biotechnology company specializing in the field of kidney disease and related treatments, established in 2021. After the transaction is completed, the pharmaceutical company will be integrated into Novartis China as a whole. Novartis announced in a statement that this acquisition is expected to expand the company's kidney disease product portfolio in China, enrich future product lines, and better meet the treatment needs of kidney disease patients in China.
It is reported that Xinruinuo Pharmaceutical's core assets include two drugs in the clinical development stage, namely atrasentan and zigakibart (BION-1301), both used for the treatment of IgA nephropathy. IgA nephropathy is a progressive kidney disease that mainly affects young people, and currently targeted treatment options are limited. Xinruinuo Pharmaceutical has the exclusive right to develop and commercialize these two assets in the Asian region.
Zhang Ying, President and Managing Director of Novartis China, publicly stated that the agreement is fully aligned with Novartis's strategy of focusing on innovative drugs in four core treatment areas, including cardiovascular, renal and metabolic, immune, neuroscience, and oncology. After integration, Novartis will leverage its experience in drug development and commercialization to accelerate the commercial launch of Xinruinuo Pharmaceutical's research product line, providing assistance to kidney disease patients in need.